Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis
Takayoshi Kanie, Atsushi Mizuno, Daisuke Yoneoka, Wilson Tam, Jakub Morze, Andrzej Rynkiewicz, Yiqiao Xin, Olívia Wu, Joey SW Kwong
Abstract
Objectives: \nThis is a protocol for a Cochrane Review (intervention). The objectives are as follows: \n \nTo systematically review the available evidence on the effects (benefits and harms) of DPP‐4 inhibitors, GLP‐1 receptor agonists, and SGLT‐2 inhibitors in people with established CVD, using network meta‐analysis.
Topics & Concepts
Dipeptidyl peptidase-4TransporterPharmacologyGlucagon-like peptide 1 receptorGlucagon-like peptide-1MedicineReceptorDiabetes mellitusChemistryInternal medicineType 2 diabetesEndocrinologyBiochemistryAgonistGeneDiabetes Treatment and ManagementHeart Failure Treatment and ManagementNeuroendocrine Tumor Research Advances